Based in South San Francisco, Denali Therapeutics reported positive Phase I data and regulatory progress for two therapeutics the company is developing for amyotrophic lateral sclerosis (ALS). They reported the results at the virtual 2021 Annual Northeast ALS (NEALS) Meeting held on October 6–7.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,